Eli Lilly is set to enter into a deal worth over USD 2 billion with Hong Kong-based Insilico Medicine to accelerate drug discovery using artificial intelligence, signaling a major push toward AI-driven pharmaceutical innovation.

The collaboration will focus on leveraging Insilico’s AI platforms to identify and develop novel drug candidates across multiple therapeutic areas. The agreement reflects Lilly’s broader strategy to integrate advanced technologies into its R&D pipeline, aiming to reduce development timelines and improve success rates in drug discovery.

Under the terms of the deal, Insilico Medicine will be eligible for milestone payments and royalties linked to the development and commercialization of drug candidates. The partnership highlights the growing importance of AI in transforming traditional pharmaceutical R&D models, enabling faster identification of promising molecules and more efficient clinical progression.

The move comes amid increasing industry-wide adoption of AI-driven platforms to address challenges such as rising drug development costs, lengthy timelines, and high failure rates. By combining Lilly’s global development and commercialization capabilities with Insilico’s AI expertise, the collaboration aims to accelerate the delivery of innovative therapies to patients.

This partnership also underscores a broader trend of cross-border collaborations, with global pharmaceutical companies increasingly partnering with tech-driven biotech firms in Asia to access cutting-edge innovation.

As AI continues to reshape drug discovery, such large-scale partnerships are expected to play a pivotal role in redefining pharmaceutical R&D, making it more data-driven, efficient, and scalable.